Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
Filed with HKEX · Stock code 9688 · · 11 pages · English
Summary by 6ix AI
It confirms the total authorized share capital and provides details on issued shares and treasury shares. The report also includes a public float sufficiency confirmation and outlines the movements in share options under various equity incentive plans. Overall, there were no increases or decreases in issued or treasury shares during the month.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zai Lab's next earnings callZai Lab (HKEX:9688) Q3 2026 Earnings Call · Nov 5, 2026 at 8:00 AM ESTRegister
Earlier from Zai Lab
- Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
- Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
- Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
- Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
- Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Later from Zai Lab
- Charter of the nominating and corporate governance committee
- Private placement of american depositary shares and issuance of underlying shares under general mandate
- Overseas regulatory announcement - form 8-K
- Inside information - update on first data from global phase 1B clinical trial
- Notice of audit committee action
Follow Zai Lab into a list and get an email when it puts out news.
Follow Zai Lab